Sofosbuvir-Based Therapies for Patients with Hepatitis C Virus Infection: Real-World Experience in China

Table 3

SVR12 by baseline factors.

	SVR12 rates
	n/total (%)		P value
Total	216/226 (96%)	—	—
By regimen		3.756	0.153
SOF+DCV	89/96 (93%)
SOF+LDV	96/99 (97%)
SOF+VEL	31/31 (100%)
By gender		0.200	0.655
male	114/120 (95%)
female	102/106 (96%)
By treatment history		2.712	0.100
treatment naïve	122/125 (98%)
treatment experience	94/101 (93%)
By HCV genotype		0.908	0.322
GT 1b	137/140 (98%)
GT 6a	45/45 (100%)
		19.306	<0.001
GT 3	17/22 (77%)
Not GT 3	199/204 (98%)
By HCVRNA, log10 IU/ml		0.254	0.614
<10^6	104/108 (96%)
≥10^6	112/118 (95%)